Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for sharing this. Big Pharma Gilead listing our gp41 and ITV-1 in their updating patents is like writing “We know all about your tech and believe in it.” Since Gilead has already written on their webpage they are looking for a combination treatment immune modulator to go with their drug Veklury for Covid this makes complete sense for them to be looking at ITV-1 as an immune modulator- the toxicity reports are good. Now we know its more than just Gilead looking- its involving updating Gilead patents with ENZC data included. Just a matter of time here. $ENZC
https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-veklury
Those are some big company name drops for an executive to be mentioning in a PR. Great DD!
Katz out of the bag, no more Blank check. Good financials share structure with fda in tow, follow the money dude on the bid, reset, 52 week high blue sky, eye on fibs
Great DD Detached. Grateful to be included with you and War on BYOC.
ENZC and it monoclonal antibodies can be developed into antibody drug conjugates (ADCs) which are the future of medicine. We are ahead of the curve in the new molecular generation of drugs. $ENZC
“ADCs are still in early stages of clinical application. However, with improved technology, the clinical application of ADC is rapidly accelerating and hold the potential to bring forth a new generation of cancer therapeutics.”
https://www.google.com/amp/s/www.nasdaq.com/articles/3-biotech-technological-developments-to-watch-out-for-in-2021-2021-01-07%3famp
Don’t let the distractions from the science prevent you from taking a more informed look at SBFM and what they are working on with UoG as a therapeutic pill to take at home for Covid. Read the science based articles (links below) put out by USA Today and written based on the Covid research done at the UniversityofGeorgia.edu. The science articles are centered on the University of Georgia’s research of the compound inhibitors developed and that SBFM has licensed and are now testing in mice with their own previously developed compounds. IMO the UoG studies covered everything including toxicology! Read about the UoG scientists background that were involved at UoG in this study in particular and their making of compound protease inhibitors and how they capitalized on research already done 12 years ago with SARs.
A quote from one of the articles whose links are below: “These compounds, naphthalene-based PLpro inhibitors, are shown to be effective at halting SARS-CoV-2 PLpro activity as well as replication. They offer a potential rapid development path to generating PLpro-targeted therapeutics for use against SARS-CoV-2.” This research is led by Scott Pegan, Director of UGA Center of Drug Discovery. $SBFM
https://www.google.com/amp/s/news.uga.edu/promising-path-found-covid-19-therapeutics/amp/
https://www.sec.gov/Archives/edgar/data/1402328/000165495420011251/sbfm_ex991.htm
A bunch of gangsters in the house now. IMO bottoms in. $ENZC
Go ahead and DUMP your shares. You will be glad when it’s over with and can do other things. I am backing up the semi’s and will be waiting and calmly filling them up with the shares in the .002s.
Amazing post! Thank you bluebird50
Direct from the Gilead website: “We are also collaborating with other companies to evaluate combination treatment of Veklury with immune-modulating therapies, with the hope of improving patient outcomes.” GodFather on point. IMO Gilead will buyout/license ENZC tech and put in use ITV-1 for immune-modulating therapies for combination treatment with Veklury and ENZC will be doing the share buyback. With Covid the audit will be sped up for completion purposes so other activities can be finalized. All things are considered dire as if in war time due to Covid and ENZC being in the business of saving lives. Innovative new MonAbs Infusion Centers will be popping up and located in every major city hospital.
https://www.gilead.com/purpose/advancing-global-health/covid-19 $ENZC
Great job to you Mick, Golden, BB and NurseTrader for great DD!
Buyout or big partnership tba? Zimbler cant be the only one funding all their activities now $CNGT
Cramer just trying to get cheapies with the sarcasm. He missed the flush down to .30s. Up we go today. Strong hands and institutional loading. MonAbs infusion centers will be in every hospital in America soon. $ENZC
Thank you Sello! Glad you are here. Amazing DD!
UK Covid variant will be the most dominant in the US come March. “monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant.” IMO ENZC will partner up with another big pharma to get a piece of the monoclonal antibody market by March. This is just the beginning of pharma competition and the MonAbs market is heating up fast due to the Covid variants. https://www.google.com/amp/s/www.news-medical.net/amp/news/20210204/Pfizer-vaccine-and-Eli-Lilly-monoclonal-antibodies-successfully-neutralize-SARS-CoV-2-UK-variant-finds-study.aspx
“Many health insurers, including Medicare and Medicaid, will make payments to health care providers that furnish monoclonal antibodies (mAbs) used to treat COVID-19.”
IMO $ENZC MonAbs coming soon to an infusion center near you. MonAbs infusion center locator links below.
https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Documents/Monoclonal-Antibody-Infusion-Center-Model-508.pdf
https://www.hhs.gov/about/news/2021/01/11/hhs-launches-web-based-locator-for-covid-19-outpatient-treatment-sites-for-monoclonal-antibodies.html
https://covid.infusioncenter.org/
Short Squeeze get your tickets North bound Chooo Choooo Insiders buying
Chief Scientific Officer of the Biden Administration Dr Kessler “Seek out monoclonal antibody treatment. It is not being used enough and can keep 70% of patients with COVID -19 out of the hospital and save lives.” HUGE need for ENZCs monoclonal antibody treatment right now. If ENZC gets just 1% of the monoclonal antibody market its stock price should be $1.00 minimum. ENZC partner up and open up the infusion centers and lets get Clone3 out to the public. ENZC next PR will be about what they are doing further to make this happen now. $ENZC
Good Radiogel video for newbies: https://www.youtube.com/embed/QzSDs_7hzBk
Todays PR: “The Company's ITV-1 peptide was tested against human corona virus 229E Strain (HCoV-229E) and exhibited comparable efficacy but with a 20-fold lower toxicity than the widely used anti-influenza medicine Tamiflu®.” Perhaps the news from todays PR was what Gilead was waiting on for forming a partnership with Enzolytics and licensing of ITV-1 for immune-modulating therapies for combination treatment with Veklury.
https://www.gilead.com/purpose/advancing-global-health/covid-19 $ENZC
Todays PR: “The Company's ITV-1 peptide was tested against human corona virus 229E Strain (HCoV-229E) and exhibited comparable efficacy but with a 20-fold lower toxicity than the widely used anti-influenza medicine Tamiflu®.” Now read this- “the U.S. government has spent more than $1.5 billion stockpiling Tamiflu since 2005 as part of the nation’s pandemic preparedness plan.” They will soon have a less toxic and just as effective drug to choose- ITV-1
https://www.accesswire.com/629824/Enzolytics-Inc-Reports-Test-Results-of-its-Patented-ITV-1-Conducted-at-the-National-Centre-of-Infectious-and-Parasitic-Diseases
https://www.google.com/amp/s/amp.theatlantic.com/amp/article/307801/
Podcast news about the company open and more than willing to do a buy back of shares if the stock price continues to remain at a discount was outstanding.
Bawahahahahaha. Post of the day!
Keep singing bluebird50 and have a good week.
CEO Charles Cotropia in the interview states “We do know that our identified initial target on the CoronaVirus is significantly different from the targets of the antibodies produced by Regeneron and Eli Lily. Thus, with a combination of our proposed broadly neutralizing anti-CoronaVirus antibodies, the administration of a “cocktail” of several antibodies could be expected to produce a more significant neutralizing effect.”
If a cocktail of several different monoclonal antibodies is expected to better neutralize Corona Virus, it would be advantageous for Eli Lily and Enzolytics to have a partnership. IMO it seems like CEO Cotropia almost tells you there is a partnership with Lily in this interview. $ENZC
https://www.ceocfointerviews.com/enzolytics20.html
RIP Shell Man.
Charles and Zhabolov jr have worked their entire life to get to this moment. They will not disappoint. With the stock price where it is and the momentum behind it the next pr will completely blow the lid off the top. New discoveries, partnerships, patents and licensing. Its coming. $ENZC
Clay, thank you for your work and attracting your viewers to ENZC as you are the number 1 viewed IHUB member. Keep it going! $ENZC
New investors need to listen to this interview. Great Job God_Father! ENZC gains only 1% of the monoclonal antibody market it puts the ENZC share price at $1.00! $ENZC
Massive accumulation. Over $30 million dollars traded over .50 so far today. Buy the dips or be left behind like TrustMe when he missed the .008 train. Choo Choo $ENZC
Unlike other stocks that are running ENZC has laid the groundwork already. The catalysts that could come through are numerous. I’m looking forward to the 2 subsidiary companies created for licensing our tech. IMO these two were created because the tech was proven already and Charles and Zhaboliv jr. already had companies lined up to license the tech. Being a Cornell graduate CEO Cotropia knows in business to always have your distribution channels lined up before moving forward into production! ENZC
Shares being bought and tucked away. With big money here to stay and the float being bought up we could open .15 cents higher tomorrow and run to .90 cents easy without a pr. With a good pr we are in paper and running. $ENZC
Enzolytics is not a .50 cent company. We have the best scientists working worldwide and are working out of OWS with AI tech: the last pr states “The Discovery of Seven Newly Identified Conserved Target Sites on the HIV Virus.” Enzolytics has the tech to defeat AIDS and is working to end Covid with its proven tech. Gilead is here. ENZC has paper written all over it. Better be holding overnight now otherwise 1 after hours pr and we could gap $1 easy money. $ENZC
https://www.bloomberg.com/press-releases/2021-02-01/enzolytics-announces-the-discovery-of-seven-newly-identified-conserved-target-sites-on-the-hiv-virus
Sorry to hear this moondogaz. Lets get after it tomorrow and hit that ask to help put an end to cancer. $enzc
World Cancer Day is tomorrow. Enzolytics and it’s Irreversible Pepsin Fraction (IPF) is a therapeutic platform technology that can be used to facilitate a range of applications. IPF binds to thymus (T)-cells and turns on T helper cell type 1 (Th1) immune system responses that kill infected cells. The Company's lead compound is a suspension of IPF, which is indicated for the treatment of autoimmune diseases, such as cancer.” IPF= Cancer Killer. $ENZC
Say hello to my friend .30 God_Father. $ENZC
Agreed God_Father. The Gilead patent is a beautiful thing. Its good that they pay respect. No need to send a horses head. $ENZC
I agree. Shareholders have seen what retail can do with the likes of AMC and GME last week. To know big pharm Gilead believes in the ENZC technology and its all to end HIV. Lots of shareholders will be getting off the sidelines for this one. It just got real for a lot of people to invest. We just had the last flush- no more low volume take downs. No gaps and convertibles were negotiated to wait for 2 years to cash out. $ENZC
Patent App of Gilead states (notice ENZC’s patented technology ITV and Cl3hmAb which imo is not listed just by coincidence):
"In some embodiments, the gp41 inhibitor is selected from the group consisting of albuvirtide, enfuvirtide, griffithsin (gp41/gp120/gp160 inhibitor), BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, CPT-31, Cl3hmAb, PIE-12 trimer and sifuvirtide. In some embodiments, the a CD4 attachment inhibitor is ibalizumab or a CADA analog. In some embodiments, the gp120 inhibitor selected from the group consisting of anti-HIV microbicide, Radha-108 (receptol) 3B3-PE38, BanLec, bentonite-based nanomedicine, fostemsavir tromethamine, IQP-0831, VVX-004, and BMS-663068."
You sell, you chase now. No one should be without shares with the Gilead news. Massive opportunity buying incoming before uplisting. Disruptive news confirmed with Gilead patent. $ENZC
I agree BigJuan. Since that patent came out under the radar two weeks ago someone has been loading millions. Next week the gigs up..Timing101 to get out the pocketbooks. $ENZC